Evidence method
Level · gp.fundamentals.debt_to_revenue
342.63% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Sep 30, 2023
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-062136General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
7.33% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-123.12% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-20.72% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
51.40% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
48.98% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-134.38% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
75.25% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
40.44% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 7.56%
- Current
- 7.33%
- Delta
- -0.23%
- Previous
- -48.15%
- Current
- -123.12%
- Delta
- -74.97%
- Previous
- 12.06%
- Current
- -20.72%
- Delta
- -32.78%
- Previous
- 38.75%
- Current
- 51.40%
- Delta
- 12.65%
- Previous
- 63.39%
- Current
- 48.98%
- Delta
- -14.41%
- Previous
- -97.74%
- Current
- -134.38%
- Delta
- -36.65%
- Previous
- 65.89%
- Current
- 75.25%
- Delta
- 9.36%
- Previous
- 35.45%
- Current
- 40.44%
- Delta
- 4.99%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT CAPEX_INTENSITY_DECREASED →Transitioned To · ADPT CASH_GENERATION_DECREASED →Transitioned To · ADPT GROWTH_DECREASED →Transitioned To · ADPT INVENTORY_PRESSURE_INCREASED →Transitioned To · ADPT MARGIN_DECREASED →Transitioned To · ADPT PROFITABILITY_DECREASED →Transitioned To · ADPT R_AND_D_INTENSITY_INCREASED →Transitioned To · ADPT SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.